232 related articles for article (PubMed ID: 30340199)
1. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
Sweet K; Hazlehurst L; Sahakian E; Powers J; Nodzon L; Kayali F; Hyland K; Nelson A; Pinilla-Ibarz J
Leuk Res; 2018 Nov; 74():89-96. PubMed ID: 30340199
[TBL] [Abstract][Full Text] [Related]
2. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
Gallipoli P; Cook A; Rhodes S; Hopcroft L; Wheadon H; Whetton AD; Jørgensen HG; Bhatia R; Holyoake TL
Blood; 2014 Aug; 124(9):1492-501. PubMed ID: 24957147
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
[TBL] [Abstract][Full Text] [Related]
8. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
10. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.
Zhou A; Knoche EM; Engle EK; Fisher DA; Oh ST
Blood Cancer J; 2015 Oct; 5(10):e351. PubMed ID: 26430722
[No Abstract] [Full Text] [Related]
11. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
12. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
13. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
14. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
[TBL] [Abstract][Full Text] [Related]
16. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
18. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cortes J; Quintás-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H
Cancer; 2007 Nov; 110(9):2000-6. PubMed ID: 17849425
[TBL] [Abstract][Full Text] [Related]
20. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Chen M; Gallipoli P; DeGeer D; Sloma I; Forrest DL; Chan M; Lai D; Jorgensen H; Ringrose A; Wang HM; Lambie K; Nakamoto H; Saw KM; Turhan A; Arlinghaus R; Paul J; Stobo J; Barnett MJ; Eaves A; Eaves CJ; Holyoake TL; Jiang X
J Natl Cancer Inst; 2013 Mar; 105(6):405-23. PubMed ID: 23446755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]